The Venture Codex Logo

The Venture Codex

Circle.Co

Connect House 133-137 Alexandra Road, Wimbledon, London, London, SW19 7JY, United Kingdom

Overview

Circle & Co is an investment firm that focuses on investing in early-stage companies.

Total investments
2
Lead investments
0
Investments · 12mo
2
Active investors
0
Visit website

Investment portfolio

  • Integral

    Participated · Equity · Jul 2026

    Integral provides Forward Deployed Privacy Services that embed privacy experts directly into customer data pipelines to perform entity-preserving remediation and continuous privacy risk assessment. Its methodology is grounded in peer-reviewed statistical disclosure limitation research and was initially validated in healthcare, life sciences, and health data marketplaces. Integral produces defensibility artifacts such as Expert Determinations under HIPAA or signed defensibility opinions tailored to context, enabling enterprises and data originators to commercialize or share sensitive datasets. The company supports AI labs, data platforms, vertical AI builders, and enterprises operating in regulated environments. Following a $25 million financing, Integral plans to expand its privacy engineering and statistical methodology teams, invest in linkage and continuous assessment infrastructure, and broaden go-to-market efforts across the real-world data economy.

  • Lucis

    Participated · Seed · Dec 2025

    Founded in 2025, Lucis offers a preventive health platform that analyses more than 110 blood biomarkers and combines those results with longitudinal data and physician-reviewed AI insights to deliver personalised nutrition, supplementation, lifestyle, and follow-up testing recommendations. The company has grown rapidly to over 10,000 users across France, the UK, Ireland, and Portugal and has delivered more than one million biomarker tests. Early outcome data shows that among users who completed a six-month follow-up, 75% improved at least three biomarkers without medication, and more than 80% opted to retest; at initial testing 99.9% had at least one biomarker outside optimal ranges. Lucis operates with a team of about 20 employees, a medical board and a network of 10+ physicians providing clinical oversight. The company plans to expand into Spain, Germany, and Italy by the end of 2026 while continuing to invest in personalisation, longitudinal monitoring, and clinical safety.

Team

No current team members are available.